Physician profile
John C Coman
NPI 1770580441
$692.97
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $83.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $165.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $121.19 | 2019 | |
| Pfizer INC. | $77.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.76 | 2020 | |
| Sanofi Pasteur INC. | $24.21 | 2019 | |
| Melinta Therapeutics, LLC | $23.80 | 2019 | |
| Daiichi Sankyo INC. | $22.08 | 2019 | |
| Allergan, INC. | $19.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.26 | 2019 | |
| Novo Nordisk INC | $18.79 | 2019 | |
| Seqirus USA INC | $18.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Coman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.